A Phase 2 interventional study of Capecitabine and Exemestane in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 83 sites in 18 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-26.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.
Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 40th largest by enrollment of the 227 interventional ones that give a count, is one of 9 that started in 2013, is one of 121 in phase 2, and was the 138th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Biostar Pharma, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 146 · Phase 3 55 · Phase 4 6
First in 1998; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 309 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 54 across the 227 interventional studies. Of the 149 that completed or were terminated, 54 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 233 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 37th largest by enrollment of the 155 interventional ones that give a count, is one of 12 that started in 2013, is one of 39 in phase 2, and was the 97th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
8 of the studies testing capecitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT06016387Sunnybrook Health Sciences CentreTucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | 2026-12-31 |
| NCT06764940Biostar Pharma, Inc.A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | 2027-01-15 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
| NCT06247995Novartis PharmaceuticalsA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | 2027-04-14 |
Add all 8 to your calendar (.ics) → With an account.
Among the 233 studies testing capecitabine in Breast Neoplasms, from their registry updates:
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This was a three-arm, randomized, open label, multi-center phase II study investigating the combination of everolimus (10mg daily) with exemestane (25mg daily) versus everolimus (10mg daily) versus capecitabine (1250mg/m2 twice daily for 14 days, 3-week cycle) in patients with estrogen-receptor positive, HER2 negative, advanced breast cancer after recurrence or progression on letrozole or anastrozole.
The reference therapy (control arm) used in the course of this trial was the combination arm of everolimus plus exemestane. The investigational therapies in the context of this study were everolimus monotherapy and capecitabine monotherapy. All treatments were taken orally until disease progression, intolerable toxicity or withdrawal of patient's informed consent. Patients were randomly assigned with equal allocation to one of the treatment arms:
Treatment assignment was stratified by the presence of visceral disease (yes vs. no). Visceral refered to lung, liver, heart, ovary, spleen, kidney, adrenal gland, malignant pleural or pericardial effusion or malignant ascites.
Randomization and Treatment Phase:
At Visit 3 all eligible patients were randomized in 1:1:1 ratio to receive everolimus (10mg daily oral tablets) in combination with exemestane (25 mg daily oral tablets), everolimus (10mg daily oral tablets) or capecitabine monotherapy (1250mg/m2 twice daily orally for two weeks followed by a one week rest period in 3-weeks cycles). Assignment was stratified by the presence of visceral disease (yes vs. no). Visceral refered to lung, liver, heart, ovary, spleen, kidney, adrenal gland, malignant pleural or pericardial effusion or malignant ascites. After randomization, study treatment started and continued until progression, intolerable toxicity or consent withdrawal. Further treatment after progression and study treatment discontinuation was at the investigator's discretion. Dose adjustment (reduction, interruption) according to safety findings was allowed. Regular safety and efficacy reviews by Data Monitoring Committee (DMC) were performed. Tumor assessments were performed every 6 weeks until disease progression. Additional evaluation were performed to confirm response at 4 weeks after it was first observed. After at least 150 PFS events had been documented per RECIST 1.1 by local assessment in each of the two following groups: (i) everolimus + exemestane arm plus everolimus monotherapy arm, and (ii) everolimus + exemestane arm plus capecitabine monotherapy arm, the frequency of tumor assessments was changed to every 12 weeks or as clinically indicated.
Follow-up phase:
Patients were followed for safety for 30 days after study treatment discontinuation. If a patient did not discontinue study treatment due to disease progression, lost to follow-up or consent withdrawal, then tumor assessments continued to be performed every 6 weeks until disease progression, death, lost to follow-up or investigator decision in patient best interest.
Survival Data Collection:
All patients were followed for survival status at least every 3 months regardless of treatment discontinuation reason and up to two years after randomization of last patient. Survival information could be obtained via phone and information were documented in the source documents and eCRF. Additional survival follow-up might be performed more frequently if a survival update was required for reporting the results or to meet safety or regulatory needs.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capecitabine (1250 mg/m2 twice daily) for two weeks, followed by one week rest period in 3-weeks cycles (investigational arm).
Drug: Capecitabine
Everolimus (10 mg daily) (investigational arm).
Drug: Everolimus
Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).
Drug: Exemestane · Drug: Everolimus
Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
Also known as: Capecitabine monotherapy
Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
Also known as: Control arm
Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
Also known as: Everolimus monotherapy, RAD001
Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone
Progression Free Survival (PFS) is defined as the time from date of randomization to the date of first radiologically documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. PFS was compared between the everolimus + exemestane combination therapy with the everolimus monotherapy.
Time frame: Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to 39 months
Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Capecitabine Alone
Progression Free Survival (PFS) is defined as the time from date of randomization to the date of first radiologically documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. PFS was compared between the everolimus + exemestane combination therapy with the everolimus monotherapy.
Time frame: Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to 39 months
Overall Survival (OS)
Overall Survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died by the date of analysis cut-off, OS was censored at the date of last known date patient alive.
Time frame: Every 3 months following end of treatment visit, assessed for approximately 54 months
Overall Response Rate (ORR)
Overall Response Rate (ORR) as the proportion of patients whose best overall response is either complete response (CR) or partial response (PR) according to RECIST 1.1 This was assessed in the full patient population. Complete response is achieved when all lesions evaluated at baseline are absent at subsequent visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Only descriptive statistics.
Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 43 months
Clinical Benefit Rate (CBR)
Clinical Benefit Rate (CBR) is defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) or Non-CR/non-PD lasting more than 24 weeks based on local investigator's assessment according to RECIST 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, Stable disease (SD), neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD; CBR = CR+PR+SD. Only descriptive statistics.
Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 43 months
Time to Eastern Cooperative Oncology Group (ECOG) Performance Deterioration
The Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale used to assess physical health of subjects,ranging from 0 (most active) to 5 (least active). Definitive deterioration is defined as no improvement in the ECOG status following observation of the deterioration.
Time frame: Baseline, every 6 weeks up to about 43 months
Time to 10% Definitive Deterioration in the Global Health Status / Quality of Life
The global health status/QoL scale score of the QLQ-C30 is identified as the primary PRO variable of interest. Physical Functioning (PF), Emotional Functioning (EF) and Social Functioning (SF) scale scores of the QLQ-C30. The time to definitive 10% deterioration is the number of days between the date of randomization and the date of the assessment at which definitive deterioration is seen. Definitive 10% (5-point) deterioration is defined as a decrease in score by at least 10% (5-points) compared to baseline, with no later increase above this threshold observed during the course of the study.
Time frame: Baseline, every 6 weeks up to about 43 months
Mean Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Between Week 3 and 12
TSQM was used to measure the Patients' self-reported satisfaction or dissatisfaction with the study treatment. The differences in mean scale scores between weeks 3 and 12 comparing treatment satisfaction in the different treatment arms: everolimus + exemestane combination therapy versus everolimus monotherapy, and everolimus + exemestane combination therapy versus capecitabine monotherapy. The TSQM version 1.4 domain scores range from 0 to 100 with higher scores representing a higher satisfaction on that domain.
Time frame: Week 3, Week 12
This study was conducted at 84 centers in 18 countries worldwide: Belgium (1), Denmark (6), Hungary (3), Ireland (3), Spain (4), Sweden (6), United Kingdom (3), United States (19), Argentina (6), Brazil (5), Peru (4), India (4), Lebanon (5), Malaysia (2), Russia (3), Thailand (3), Turkey (3) Australia (4)
| Milestone | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| Started | 104 | 103 | 102 |
| Safety set | 104 | 103 | 102 |
| Completed | 0 | 0 | 0 |
| Not completed | 104 | 103 | 102 |
| Withdrew: Adverse event | 9 | 20 | 19 |
| Withdrew: Disease progression | 76 | 66 | 64 |
| Withdrew: Death | 2 | 2 | 2 |
| Withdrew: Protocol violation | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 6 | 8 | 9 |
| Withdrew: Administrative problems | 2 | 0 | 1 |
| Withdrew: Physician decision | 8 | 6 | 5 |
| Milestone | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| Started | 96 | 93 | 91 |
| Completed | 0 | 0 | 0 |
| Not completed | 96 | 93 | 91 |
| Withdrew: Disease progression | 7 | 8 | 11 |
| Withdrew: Death | 9 | 7 | 5 |
| Withdrew: Withdrawal by subject | 4 | 8 | 8 |
| Withdrew: Administrative problems | 0 | 1 | 0 |
| Withdrew: New cancer therapy | 7 | 16 | 15 |
| Withdrew: Followup phase completed as per protocol | 69 | 53 | 52 |
Progression Free Survival (PFS) is defined as the time from date of randomization to the date of first radiologically documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. PFS was compared between the everolimus + exemestane combination therapy with the everolimus monotherapy.
| Months | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg |
|---|---|---|
| Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone | 8.41 (6.60 to 9.72) | 6.77 (5.52 to 7.20) |
Progression Free Survival (PFS) is defined as the time from date of randomization to the date of first radiologically documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. PFS was compared between the everolimus + exemestane combination therapy with the everolimus monotherapy.
| Months | Everolimus 10 mg + Exemestane 25 mg | Capecitabine 1250 mg/m2 |
|---|---|---|
| Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Capecitabine Alone | 8.41 (6.60 to 9.72) | 9.59 (8.25 to 15.05) |
Overall Survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died by the date of analysis cut-off, OS was censored at the date of last known date patient alive.
| Months | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| Overall Survival (OS) | 23.06 (19.48 to 27.96) | 29.27 (24.28 to 31.77) | 25.56 (23.82 to 33.35) |
Overall Response Rate (ORR) as the proportion of patients whose best overall response is either complete response (CR) or partial response (PR) according to RECIST 1.1 This was assessed in the full patient population. Complete response is achieved when all lesions evaluated at baseline are absent at subsequent visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Only descriptive statistics.
| Percentage of Participants | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| Overall Response Rate (ORR) | 21 (13.9 to 27.8) | 12 (6.9 to 18.2) | 23 (15.9 to 30.4) |
Clinical Benefit Rate (CBR) is defined as the proportion of participants with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) or Non-CR/non-PD lasting more than 24 weeks based on local investigator's assessment according to RECIST 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, Stable disease (SD), neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD; CBR = CR+PR+SD. Only descriptive statistics.
| Percentage of Participants | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| Clinical Benefit Rate (CBR) | 59 (48.2 to 65.0) | 43 (33.5 to 50.3) | 53 (43.4 to 60.5) |
The Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale used to assess physical health of subjects,ranging from 0 (most active) to 5 (least active). Definitive deterioration is defined as no improvement in the ECOG status following observation of the deterioration.
| Weeks | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| Time to Eastern Cooperative Oncology Group (ECOG) Performance Deterioration | 72.57 (38.71 to NA) | 126.57 (72.14 to NA) | 120.00 (72.57 to NA) |
The global health status/QoL scale score of the QLQ-C30 is identified as the primary PRO variable of interest. Physical Functioning (PF), Emotional Functioning (EF) and Social Functioning (SF) scale scores of the QLQ-C30. The time to definitive 10% deterioration is the number of days between the date of randomization and the date of the assessment at which definitive deterioration is seen. Definitive 10% (5-point) deterioration is defined as a decrease in score by at least 10% (5-points) compared to baseline, with no later increase above this threshold observed during the course of the study.
| Weeks | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| Time to 10% Definitive Deterioration in the Global Health Status / Quality of Life | 30.86 (24.29 to 78.00) | 23.86 (12.57 to 24.71) | 61.29 (36.86 to 143.71) |
TSQM was used to measure the Patients' self-reported satisfaction or dissatisfaction with the study treatment. The differences in mean scale scores between weeks 3 and 12 comparing treatment satisfaction in the different treatment arms: everolimus + exemestane combination therapy versus everolimus monotherapy, and everolimus + exemestane combination therapy versus capecitabine monotherapy. The TSQM version 1.4 domain scores range from 0 to 100 with higher scores representing a higher satisfaction on that domain.
| Unit on a scale | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| Side-effects | -4.8 ± 28.88 | -9.1 ± 21.88 | -2.6 ± 22.45 |
| Effectiveness | -2.2 ± 20.15 | 1.2 ± 26.51 | 1.2 ± 21.61 |
| Convenience | -0.6 ± 12.00 | 1.0 ± 16.41 | 0.5 ± 17.67 |
| Global satisfaction | -1.0 ± 17.32 | 1.8 ± 20.80 | 2.3 ± 16.96 |
On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 224 weeks (treatment duration ranged from 1.3 to 220.0 weeks). Deaths post treatment survival follow up were collected after the on- treatment period, up to approximately 5 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.
| Participants | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| On-treatment deaths | 9 | 5 | 2 |
| Post-treatment deaths | 62 | 55 | 57 |
| All deaths | 71 | 60 | 59 |
Collected over Adverse events were collected from First Patient First Treatment (FPFT) up to 30 days after study drug discontinuation, for a maximum duration of 224 weeks (treatment duration ranged from 1.3 to 220.0 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus 10 mg + Exemestane 25 mg | 9/104 (8.7%) | 37/104 (35.6%) | 103/104 (99%) |
| Everolimus 10 mg | 5/103 (4.9%) | 30/103 (29.1%) | 100/103 (97.1%) |
| Capecitabine 1250 mg/m2 | 2/102 (2%) | 30/102 (29.4%) | 99/102 (97.1%) |
| Event | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| PneumoniaInfections and infestations | 8/104 | 4/103 | 2/102 |
| Deep vein thrombosisVascular disorders | 0/104 | 0/103 | 4/102 |
| Acute kidney injuryRenal and urinary disorders | 3/104 | 4/103 | 2/102 |
| General physical health deteriorationGeneral disorders | 4/104 | 0/103 | 0/102 |
| DiarrhoeaGastrointestinal disorders | 1/104 | 2/103 | 3/102 |
| VomitingGastrointestinal disorders | 2/104 | 1/103 | 3/102 |
| DehydrationMetabolism and nutrition disorders | 1/104 | 1/103 | 3/102 |
| HypotensionVascular disorders | 0/104 | 0/103 | 3/102 |
| AnaemiaBlood and lymphatic system disorders | 1/104 | 3/103 | 1/102 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/104 | 3/103 | 0/102 |
| Event | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 |
|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 3/104 | 3/103 | 62/102 |
| DiarrhoeaGastrointestinal disorders | 36/104 | 34/103 | 55/102 |
| NauseaGastrointestinal disorders | 35/104 | 21/103 | 52/102 |
| StomatitisGastrointestinal disorders | 51/104 | 45/103 | 24/102 |
| FatigueGeneral disorders | 39/104 | 32/103 | 34/102 |
| CoughRespiratory, thoracic and mediastinal disorders | 37/104 | 16/103 | 18/102 |
| Decreased appetiteMetabolism and nutrition disorders | 35/104 | 32/103 | 27/102 |
| AnaemiaBlood and lymphatic system disorders | 32/104 | 26/103 | 22/102 |
| Weight decreasedInvestigations | 31/104 | 25/103 | 15/102 |
| Oedema peripheralGeneral disorders | 30/104 | 22/103 | 16/102 |
| Age, Continuous(Years) | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 | Total |
|---|---|---|---|---|
| Mean | 60.9 ± 10.47 | 61.3 ± 9.08 | 59.7 ± 10.50 | 60.6 ± 10.03 |
| Sex: Female, Male(Participants) | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 | Total |
|---|---|---|---|---|
| Female | 104 | 103 | 102 | 309 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 | Total |
|---|---|---|---|---|
| Caucasian | 78 | 85 | 91 | 254 |
| Black | 1 | 2 | 0 | 3 |
| Asian | 11 | 8 | 8 | 27 |
| Native American | 3 | 2 | 0 | 5 |
| Other | 11 | 6 | 3 | 20 |
| ECOG Performance Status(Participants) | Everolimus 10 mg + Exemestane 25 mg | Everolimus 10 mg | Capecitabine 1250 mg/m2 | Total |
|---|---|---|---|---|
| No Restrictions | 54 | 48 | 57 | 159 |
| Only Light Work | 42 | 50 | 39 | 131 |
| Only Self Care | 5 | 3 | 4 | 12 |
| Missing | 3 | 2 | 2 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Feb 2013 to primary completion in Jul 2018, 64 months.
Results were first posted in Feb 2021, 2 years 7 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 64 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Capecitabine · Everolimus